DIAGNOS Inc.
TSX VENTURE : ADK

DIAGNOS Inc.

June 22, 2015 11:31 ET

DIAGNOS Announces Contract with Global Pharmaceutical Company in Mexico

BROSSARD, QUEBEC--(Marketwired - June 22, 2015) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services, including screening, software and algorithm development, data analysis, and image processing, announces today a contract for diabetic-retinopathy screening with a global pharmaceutical company and its subsidiary in Mexico. DIAGNOS will provide turn-key screening services including staff, software, equipment, and transportation to screen thousands of diabetic patients in Mexico City and the Mexican states of Toluca, Chiapas, and San Luis Potosí. Screening will be offered to diabetics affiliated with different Mexican Public Health institutions and will test the impact of including preventive screening programs into the primary care clinics that follow the majority of the Mexican diabetic population.

Diabetic retinopathy is the most common diabetic eye disease and the leading cause of blindness around the world. It is a treatable disease that has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to severe stages, so early detection is critical to helping the prevention of vision loss. Mexico has a population of 132 million and, according to the International Diabetes Federation, has 15 million diabetics, 6th largest in the world.

"We are excited to increase our operations in Mexico through this pharmaceutical company and begin screening for diabetic retinopathy. Following the expected success of this project, we intend to expand the scope of services offered through this pharmaceutical company into other cities and regions in Mexico in the same way it has been done in other countries. The large majority of the diabetic population in Mexico does not receive regular screening for diabetic retinopathy (under 5%), so we are poised to deliver screening through the use of CARA, our powerful technological solution," said Mr. Guillermo Moreno, Director of Business Development at DIAGNOS.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining to improve decision making.. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care and comprises image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image-enhancement algorithms make standard retinal images sharper, clearer, and easier to read. EMR compatible, CARA is accessible securely over the internet, and compatible with all recognized image formats and brands of fundus cameras.. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • DIAGNOS Inc.
    Andre Larente, President and CEO
    1-877-678-8882 or (450) 678-8882, ext.: 224
    alarente@diagnos.ca